Stavros Stavrakis to Anti-Arrhythmia Agents
This is a "connection" page, showing publications Stavros Stavrakis has written about Anti-Arrhythmia Agents.
Connection Strength
2.717
-
Rhythm vs Rate Control Strategy for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol. 2024 Jul; 10(7 Pt 1):1395-1405.
Score: 0.885
-
Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circ Arrhythm Electrophysiol. 2019 09; 12(9):e007414.
Score: 0.638
-
Wide complex tachycardia in the presence of class I antiarrhythmic agents: a diagnostic challenge. Ann Noninvasive Electrocardiol. 2014 May; 19(3):289-92.
Score: 0.424
-
Antiarrhythmic effects of vasostatin-1 in a canine model of atrial fibrillation. J Cardiovasc Electrophysiol. 2012 Jul; 23(7):771-7.
Score: 0.383
-
Neuroscientific therapies for atrial fibrillation. Cardiovasc Res. 2021 06 16; 117(7):1732-1745.
Score: 0.181
-
Comparison of QT Interval Readings in Normal Sinus Rhythm Between a Smartphone Heart Monitor and a 12-Lead ECG for Healthy Volunteers and Inpatients Receiving Sotalol or Dofetilide. J Cardiovasc Electrophysiol. 2016 07; 27(7):827-32.
Score: 0.127
-
Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. J Am Coll Cardiol. 2009 Sep 29; 54(14):1309-16.
Score: 0.080